BR0316158A - Vacina de vetor adenoviral - Google Patents
Vacina de vetor adenoviralInfo
- Publication number
- BR0316158A BR0316158A BR0316158-7A BR0316158A BR0316158A BR 0316158 A BR0316158 A BR 0316158A BR 0316158 A BR0316158 A BR 0316158A BR 0316158 A BR0316158 A BR 0316158A
- Authority
- BR
- Brazil
- Prior art keywords
- vector
- administering
- effective amount
- immune response
- generating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"VACINA DE VETOR ADENOVIRAL". São fornecidos vetores adenoviral para geração de uma resposta imune ao antígeno. Os vetores compreendem uma unidade de transcrição que codifica um polipeptídeo secretável, o polipeptídeo compreendendo uma seq³ência de sinal secretora acima de um antígeno tumoral acima de ligante CD40, que é desprovido de todo ou substancialmente todo o domínio de transmembrana que torna o CD40L secretável. Também são fornecidos métodos de geração de uma resposta imune contra células que expressam um antígeno tumoral pela administração de uma quantidade eficaz do vetor da invenção. Além disso, são fornecidos métodos de geração de uma resposta imune contra câncer que expressa um antígeno tumoral em um indivíduo pela administração de uma quantidade eficaz do vetor da invenção. Ainda são fornecidos métodos de geração de imunidade a infecção por papiloma vírus humano (HPV) pela administração de uma quantidade eficaz do vetor da invenção que codifica a proteína E6 ou E7 de HPV. A imunidade gerada é de longa duração.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42528602P | 2002-11-12 | 2002-11-12 | |
PCT/US2003/036237 WO2004044176A2 (en) | 2002-11-12 | 2003-11-12 | Adenoviral vector vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0316158A true BR0316158A (pt) | 2005-09-27 |
Family
ID=32312964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0316158-7A BR0316158A (pt) | 2002-11-12 | 2003-11-12 | Vacina de vetor adenoviral |
Country Status (10)
Country | Link |
---|---|
US (5) | US8119117B2 (pt) |
EP (1) | EP1563074B1 (pt) |
JP (1) | JP2006506072A (pt) |
KR (1) | KR101114784B1 (pt) |
CN (1) | CN1756845A (pt) |
AU (1) | AU2003295502A1 (pt) |
BR (1) | BR0316158A (pt) |
CA (1) | CA2509980C (pt) |
MX (1) | MXPA05005051A (pt) |
WO (1) | WO2004044176A2 (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1563074B1 (en) | 2002-11-12 | 2018-01-10 | VAXum, LLC. | Adenoviral vector vaccine |
US8299229B2 (en) | 2003-11-24 | 2012-10-30 | Microvax, Llc | Mucin antigen vaccine |
US8828957B2 (en) | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
US20060286074A1 (en) * | 2005-05-31 | 2006-12-21 | Yucheng Tang | Methods for immunotherapy of cancer |
US9533036B2 (en) | 2005-11-07 | 2017-01-03 | Microvax, Llc | Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein |
US8137674B2 (en) * | 2006-04-19 | 2012-03-20 | Postech Foundation | Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer |
US10293040B1 (en) * | 2006-11-06 | 2019-05-21 | Microvax, Llc | Pharmaceutical compositions and methods of blocking Bacillus anthracis |
CN101550181B (zh) * | 2008-04-03 | 2011-08-03 | 清华大学深圳研究生院 | 人***瘤病毒16型e7蛋白功能拮抗肽及其编码基因与应用 |
EA027784B1 (ru) | 2008-05-26 | 2017-09-29 | Кадила Хелзкэр Лимитед | Комбинированная вакцина против кори и вируса папилломы человека |
CN101696231B (zh) * | 2009-09-29 | 2012-09-05 | 刘日廷 | 人***瘤病毒58型e6蛋白的抗原表位最小基序肽 |
CN107098958B (zh) * | 2010-03-26 | 2021-11-05 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
CA2884704C (en) | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
MX369173B (es) | 2013-12-24 | 2019-10-30 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista. |
CN106103483A (zh) | 2014-01-13 | 2016-11-09 | 贝勒研究院 | 抗hpv和hpv相关的疾病的新疫苗 |
WO2016153995A1 (en) * | 2015-03-20 | 2016-09-29 | The Trustees Of The University Of Pennsylvania | Vaccines with cd40 ligand as an adjuvant |
US11154603B1 (en) | 2015-11-10 | 2021-10-26 | Microvax, Llc | Burkholderia pseudomallei composition |
US10149899B1 (en) | 2015-12-11 | 2018-12-11 | Microvax, Llc | Composition and method against C-difficile |
CA3014056A1 (en) * | 2016-02-11 | 2017-08-17 | Nant Holdings Ip, Llc | Subcutaneous delivery of adenovirus with dual targeting |
BR112018016461A2 (pt) | 2016-02-12 | 2019-10-01 | Janssen Pharmaceutica Nv | anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos |
CA3014252A1 (en) | 2016-02-12 | 2017-08-17 | Nantomics, Llc | High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies |
MX2018012469A (es) | 2016-04-15 | 2019-07-04 | Immunext Inc | Anticuerpos vista antihumanos y uso de los mismos. |
WO2017192924A1 (en) * | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
CN109890408A (zh) * | 2016-05-27 | 2019-06-14 | 埃特彼塞斯公司 | 新表位疫苗组合物及其使用方法 |
CA3032688A1 (en) * | 2016-08-02 | 2018-02-08 | Nantcell, Inc. | Transfection of dendritic cells and methods therefor |
US11839655B2 (en) | 2017-09-01 | 2023-12-12 | Microvax, Llc | Combination cancer therapy |
GB201804468D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | ***新抗原及其用途 |
AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
BR112022021797A2 (pt) * | 2020-05-06 | 2022-12-13 | Navicure Biopharmaceuticals Ltd | Proteínas de fusão para imunoterapia contra o câncer e doenças infecciosas |
US20230241193A1 (en) * | 2022-02-03 | 2023-08-03 | Microvax, Llc | mRNA VACCINE DESIGN USING MULTIPLE INTERACTING IMMUNO-STIMULATORY PATHWAYS, FOR CANCER AND INFECTIOUS DISEASES |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1054937A (en) | 1975-01-28 | 1979-05-22 | Gursaran P. Talwar | Antipregnancy vaccine |
DE3431140A1 (de) | 1984-08-24 | 1986-03-06 | Behringwerke Ag, 3550 Marburg | Enhancer fuer eukaryotische expressionssysteme |
US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
NZ222509A (en) | 1986-11-19 | 1993-03-26 | Oncogen | Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen |
US6133029A (en) | 1988-03-21 | 2000-10-17 | Chiron Corporation | Replication defective viral vectors for infecting human cells |
US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US6080569A (en) | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
US5874085A (en) | 1993-11-10 | 1999-02-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Vaccine for enhanced production of IgA antibodies |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
EP0789774A2 (en) | 1994-10-03 | 1997-08-20 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
US5641665A (en) | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
GB9501079D0 (en) | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
ATE324435T1 (de) | 1995-02-21 | 2006-05-15 | Cantab Pharmaceuticals Res Ltd | Virale zubereitungen, vektoren, immunogene und impfstoffe |
WO1996029421A1 (en) | 1995-03-23 | 1996-09-26 | Cantab Pharmaceuticals Research Limited | Vectors for gene delivery |
US6096534A (en) | 1995-05-22 | 2000-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells |
US6224870B1 (en) | 1997-01-24 | 2001-05-01 | Genitrix, Ltd. | Vaccine compositions and methods of modulating immune responses |
US6017527A (en) | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
AU705647B2 (en) | 1996-07-10 | 1999-05-27 | Immunex Corporation | Method of activating dendritic cells |
BR9712852A (pt) | 1996-10-23 | 1999-11-16 | Univ Pennsylvania | Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado |
WO1998021350A1 (en) | 1996-11-13 | 1998-05-22 | Board Of Regents, The University Of Texas System | Diminishing viral gene expression by promoter replacement |
US5891432A (en) | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
US20020068048A1 (en) * | 1997-09-05 | 2002-06-06 | Patrick A. Dreyfus | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
WO2000018888A1 (en) * | 1998-09-29 | 2000-04-06 | The Uab Research Foundation | Immunomodulation by genetic modification of dendritic cells and b-cells |
US6440944B2 (en) | 1998-10-16 | 2002-08-27 | Genvec, Inc. | Methods of administering adenoviral vectors |
WO2000067761A1 (en) | 1999-05-06 | 2000-11-16 | Wake Forest University | Compositions and methods for identifying antigens which elicit an immune response |
AU1084901A (en) * | 1999-10-14 | 2001-04-23 | Martha S. Hayden-Ledbetter | Dna vaccines encoding antigen linked to a domain that binds cd40 |
US20030202963A1 (en) * | 2000-10-12 | 2003-10-30 | Cornell Research Foundation, Inc. | Method of treating cancer |
WO2002066053A2 (en) * | 2001-01-04 | 2002-08-29 | Immunex Corporation | Method of treating or preventing disease characterized by cryptococcus neoformans infection |
US6923958B2 (en) | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
US7071172B2 (en) * | 2002-04-30 | 2006-07-04 | The University Of North Carolina At Chapel Hill | Secretion signal vectors |
WO2004009789A2 (en) * | 2002-07-22 | 2004-01-29 | Vectorlogics, Inc. | Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof |
EP1563074B1 (en) | 2002-11-12 | 2018-01-10 | VAXum, LLC. | Adenoviral vector vaccine |
US8299229B2 (en) * | 2003-11-24 | 2012-10-30 | Microvax, Llc | Mucin antigen vaccine |
US8828957B2 (en) * | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
-
2003
- 2003-11-12 EP EP03786693.6A patent/EP1563074B1/en not_active Expired - Lifetime
- 2003-11-12 BR BR0316158-7A patent/BR0316158A/pt not_active IP Right Cessation
- 2003-11-12 WO PCT/US2003/036237 patent/WO2004044176A2/en active Application Filing
- 2003-11-12 CA CA2509980A patent/CA2509980C/en not_active Expired - Lifetime
- 2003-11-12 US US10/534,605 patent/US8119117B2/en not_active Expired - Fee Related
- 2003-11-12 JP JP2004552177A patent/JP2006506072A/ja active Pending
- 2003-11-12 AU AU2003295502A patent/AU2003295502A1/en not_active Abandoned
- 2003-11-12 CN CNA200380107269XA patent/CN1756845A/zh active Pending
- 2003-11-12 MX MXPA05005051A patent/MXPA05005051A/es not_active Application Discontinuation
- 2003-11-12 KR KR1020057008522A patent/KR101114784B1/ko active IP Right Grant
-
2012
- 2012-02-02 US US13/364,370 patent/US8236295B1/en not_active Expired - Lifetime
- 2012-07-16 US US13/549,581 patent/US8540979B2/en not_active Expired - Fee Related
-
2013
- 2013-08-23 US US13/974,353 patent/US9458221B2/en active Active
-
2016
- 2016-09-13 US US15/263,608 patent/US11027006B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2003295502A1 (en) | 2004-06-03 |
EP1563074A2 (en) | 2005-08-17 |
EP1563074A4 (en) | 2006-04-19 |
EP1563074B1 (en) | 2018-01-10 |
US20070269409A1 (en) | 2007-11-22 |
CA2509980A1 (en) | 2004-05-27 |
US20170065705A1 (en) | 2017-03-09 |
WO2004044176A8 (en) | 2005-09-09 |
US20120195924A1 (en) | 2012-08-02 |
WO2004044176A3 (en) | 2004-08-26 |
CA2509980C (en) | 2012-12-18 |
US20140080208A1 (en) | 2014-03-20 |
US8119117B2 (en) | 2012-02-21 |
US20120276148A1 (en) | 2012-11-01 |
US11027006B2 (en) | 2021-06-08 |
JP2006506072A (ja) | 2006-02-23 |
AU2003295502A8 (en) | 2004-06-03 |
MXPA05005051A (es) | 2006-03-10 |
WO2004044176A2 (en) | 2004-05-27 |
KR101114784B1 (ko) | 2012-02-27 |
CN1756845A (zh) | 2006-04-05 |
US8236295B1 (en) | 2012-08-07 |
KR20060010711A (ko) | 2006-02-02 |
US8540979B2 (en) | 2013-09-24 |
US9458221B2 (en) | 2016-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0316158A (pt) | Vacina de vetor adenoviral | |
Sewell et al. | Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7 | |
ES2191052T3 (es) | Vacuna polinucleotida contra el virus del papiloma. | |
NO20062948L (no) | Promotere for ekspresjon i modifisert vaccinia-virus Ankara | |
HK1028981A1 (en) | Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins | |
MY139031A (en) | Vaccine composition comprising virus-like particles of human papillomavirus | |
DE602005017743D1 (de) | Impfstoffträger für schimpansen-adenovirus | |
NO20090194L (no) | Rekombinant viral vaksine | |
SI1108035T1 (sl) | Zdravljenje raka materničnega vratu | |
NO20060813L (no) | Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav | |
EP2589604A4 (en) | SHORTEN L1 PROTEIN OF THE TYPE 52 HUMAN PAPILLOMA VIRUS | |
Pol et al. | Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning | |
ATE457030T1 (de) | Hpv-impfstoff, enthaltend peptide aus host-cell- proteinen | |
CN104918960A (zh) | 改进的人类疱疹病毒免疫疗法 | |
Mehrlatifan et al. | The structural HCV genes delivered by MPG cell penetrating peptide are directed to enhance immune responses in mice model | |
ATE297750T1 (de) | Verwendung von hsp70 protein | |
DE60126737D1 (de) | Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff | |
AU2002319501A1 (en) | Materials and methods relating to improved vaccination strategies | |
DK1290160T3 (da) | Humane Pellino-polypeptider | |
WO2004085466A3 (en) | Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use | |
Platteel et al. | Strategies to enhance immunogenicity of cDNA vaccine encoded antigens by modulation of antigen processing | |
WO2019059817A9 (en) | VACCINE BASED ON FUSION PROTEIN AND PLASMIDIC DNA | |
MX2023012707A (es) | Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos. | |
NO20061542L (no) | P185neu-Kodende DNA samt terapeutiske anvendelser derav | |
Ajorloo et al. | Immunization of mice by the co-administration of codon-optimized HPV16 E7 and lL12 genes against HPV16-associated cervical cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: YALE UNIVERSITY (US) Free format text: TRANSFERIDO DE: ALBERT B. DEISSEROTH |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |